Searching for Tissue-Specific Expression Pattern-Linked Nucleotides of UGT1A Isoforms by Zhang, Wei et al.
Searching for Tissue-Specific Expression Pattern-Linked
Nucleotides of UGT1A Isoforms
Wei Zhang
1., Wanqing Liu
1., Federico Innocenti
1,2,3, Mark J. Ratain
1,2,3*
1Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois, United States of America, 2Committee on
Clinical Pharmacology and Pharmacogenomics, The University of Chicago, Chicago, Illinois, United States of America, 3Cancer Research Center, The
University of Chicago, Chicago, Illinois, United States of America
UDP-glucuronosyltransferases 1A isoforms belong to a superfamily of microsomal enzymes responsible for glucuronidation of
numerous endogenous and exogenous compounds. The nine functional UGT1A isoforms are encoded by a single UGT1A gene
locus with multiple first exons. The expression of the UGT1A transcripts was measured by quantitative RT-PCR in 23 normal
human tissues. The tissue-specific expression patterns were observed in 13 tissues. To understand the regulation mechanism
that is responsible for the tissue-specific expression patterns, we scanned the DNA sequence alignments of the putative
promoter regions, exon 1 sequences and intron 1 sequences for those expression-pattern-linked nucleotides. Using one of the
expression-pattern-linked nucleotides for livers as an example, we showed that a database comprised of these expression-
pattern-linked nucleotides could be used to generate focused hypotheses on the problem of tissue-specific expression, which
is critical for tissue-specific pharmacodynamics of anticancer drugs.
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INTRODUCTION
Human UDP-glucuronosyltransferase (UGT) 1A is a subfamily of
UGT enzymes that glucuronidate xeno-/endobiotics and many
other substrates such as steroids and bilirubin to make the metabolic
products more easily excreted from the body via the urinary and
biliary tracts [1,2]. At least 12 UGT1A isoforms have been identified
[3]. Nucleic acid sequence analysis indicates that UGT1A2,
UGT1A11, and UGT1A12 encode pseudogenes [3].The nine
functional UGT1A isoforms (UGT1A1, UGT1A3, UGT1A4,
UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10)
are encoded by a single UGT1A gene locus with multiple first exons,
located on chromosome 2q37 [4,5]. Located in the 39 region of the
locus are exons 2–5, which encode the conserved 245 amino acids of
the carboxyl region. Each first exon is flanked by polymerase II
recognition sequences. Meanwhile, the splicing out of each intron fit
the rule of GT-AG on the exon-intron boundaries. These suggest
that each gene may be individually regulated [4,6].
Reports regarding UGT1A mRNA expression profiles indicate
that each tissue contains a selective complement of UGT1A gene
products [7]. Though not extensively studied to date, differential
expression of UGT1A isoforms has been observed in hepatic and
extrahepatic tissues [6,8]. As UGT1A genes play critical roles in
the metabolism of xeno-/endobiotics, their tissue-specific expres-
sion would be very important to organ/tissue-specific toxicity and
response to variety of drugs. Therefore, understanding the
mechanism underlying the tissue-specific expression of these genes
would be essential to the pharmacogenetics and pharmacody-
namics of drugs to be glucuronidated. However, the precise
distribution and expression of the entire UGT1A locus in human
tissues have not been systematically examined. In the present
work, quantitative real-time polymerase chain reaction (RT-PCR)
was used to detect transcripts of all of the nine functional members
of the UGT1A locus in 23 normal human tissues. Unique tissue-
specific expression patterns were observed in 13 tissues. Since
individual regulation of the unique UGT1A transcripts has not
been conclusively demonstrated and often hard to test experi-
mentally, we applied an in silico approach to search for the
expression-pattern-linked nucleotides. Due to the unique structure
of UGT1A locus, specific nucleotides in promoter regions, exon 1
sequences, intron 1 sequences may (jointly) contribute to the
observed tissue-specific expression patterns. Some possible me-
chanisms include promoter efficiency through transcription factor
binding and alternative or false splicing. Specifically, we analyzed
the putative promoter regions, exon 1 sequences and intron 1
sequences for nucleotides associated with tissue-specific expression,
focusing on the eleven tissues that had more than two expressed
UGT1A isoforms. The resulting database or pool of the
expression-pattern-linked nucleotides then could be used to
generate focused hypotheses on the regulation of the tissue-specific
expression of UGT1A isoforms.
RESULTS AND DISCUSSION
We measured the expression levels of the nine functional UGT1A
isoforms in 23 normal tissues. UGT1A genes were not expressed in
10 tissues (brain, skeletal muscle, spleen, uterus, mammary gland,
pituitary body, bone marrow, lymph node, leukocyte and all blood
fractions), while the tissue-specific expression patterns were
observed in other 13 tissues, among which placenta and lung
had only one expressed isoform (UGT1A6) (Table 1). Some
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human tissue samples are provided in Figure 1. The relative
expression levels based on the density of PCR products of the
isoforms in each tissue are shown in Table 1. Some published
tissue-specific expression patterns have been confirmed in our RT-
PCR expression data. For examples, our data confirmed that
UGT1A1, UGT1A3, UGT1A4, UGT1A6 and UGT1A9 are
expressed in livers [3,9–12], UGT1A6 is expressed in lungs [13],
UGT1A7 is expressed in kidneys [13], and UGT1A10 is expressed
in intestines [7].
UGT1A isoforms showed specific expression pattern in different
tissues. For example, in livers, only 6 UGT1A isoforms (UGT1A1,
UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A9) had
expression detected at different levels. Our major aim was to
explore an approach to study the mechanism responsible for the
observed tissue-specific expression patterns. Due to the unique
structure of the UGT1A cluster, we hypothesized that the
nucleotides that were linked to the expression patterns might
(jointly) contribute to the regulation of expression in different
tissues. A database or pool of expression-pattern-linked nucleotides
was constructed by scanning the putative promoters, intron 1
sequences as well as exon 1 sequences of the nine functional
UGT1A isoforms. The CLUSTAL W[14]-generated multiple
alignments were used to identify those specific nucleotides that had
the same pattern with the expression in a particular tissue. For
example, to search for nucleotides that may be linked to the
expression patterns of UGT1A isoforms in livers, we scanned the
multiple alignments in promoters (exon 1 sequences, intron 1
sequences) for those nucleotides that were identical in UGT1A1,
UGT1A3, UGT1A4, UGT1A5, UGT1A6 and UGT1A9 (iso-
forms expressed in livers, Table 1), but different in UGT1A7,
UGT1A8 and UGT1A10 (isoforms not expressed in livers,
Table 1). The complete database including the original nucleotide
sequences, multiple alignments and the identified nucleotides for
each tissue are provided in the supplemental materials. The
database then could be used to generate focused hypotheses that
could be tested further experimentally and/or bioinformatically.
To show an example, we used the Match [15] program to
search the TRANSFAC database [16] for potential TFBS around
one of the expression-pattern-linked nucleotides for livers. The
liver-expression-specific nucleotide closest to the TSS is a C at the
3028
th bp in the multiple alignment of 3447 bp of the putative
promoters for the six UGT1A isoforms with hepatic expression
and either a gap or a G for the three UGT1A isoforms not expres-
sed in liver (see supplemental materials). The Match program
identified a TFBS for AP-1 (activator protein 1) for three of the six
hepatically-expressed UGT1A isoforms (UGT1A3, UGT1A4,
UGT1A5). A testable hypothesis then could be that the binding
site for AP-1 close to the TSS may be contributing to the expres-
sion in liver for these three isoforms, but not the other three
hepatically-expressed isoforms. Of course, this doe not necessarily
mean that this particular transcription factor is the only deter-
minant for hepatic expression. The example just showed that we
could now use the database to prioritize our efforts and guide further
studies based on these specific nucleotides. Besides promoter
efficiency, other mechanisms such as alternative splicing may also
contribute to the observed tissue-specific expression patterns. To
generate such focused hypotheses, we could search the tissue-specific
nucleotides in our database for potential exonic or intronic splicing
enhancers [17,18]. Therefore, the identification of these expression
pattern-linked nucleotides in different tissues provided potential
working targets, both experimentally and/or bioinformatically, for
testing and generating focused hypotheses on the mechanisms
responsible for the tissue-specific expression of UGT1A isoforms.
Footnotes
The supplemental materials can be accessed at http://home.
uchicago.edu/,wzhang1/PONE/UGT1A/and will be deposited
into PharmGKB (http://www.PharmGKB.org).
MATERIALS AND METHODS
Human normal tissue samples
Complementary DNA (cDNA) from a total of 23 human normal
tissues was purchased from Clontech (Clontech Laboratories, Inc.,
Palo Alto, CA, USA). These tissues include human brain,
placenta, skeletal muscle, kidney, pancreas, spleen, thymus,
prostate, testis, ovary, small intestine, uterus, mammary gland,
thyroid, pituitary body, bone marrow, bladder, tonsil, lymph node,
leukocyte, blood fractions, liver and lung.
Expression of UGT1A isoforms in normal tissues
The expression of the UGT1A transcripts was measured in the 23
human normal tissues by PCR using TITANIUM Taq DNA
Polymerase (Clontech). Briefly, PCR was set up in a 50 ml vol reac-
tionwith3 mlofcDNAastemplate.Primersforeachexon1were59-
aacaaggagctcatggcctcc-39 (UGT1A1), 59-tgttgaacaatatgtctttggtcta-39
(UGT1A3), 59-gaaggaatttgatcgcgttac-39 (UGT1A4), 59-ggtggtggtcc-
tcaccctg-39 (UGT1A5), 59-cagctgtcctcaagagagatgtgga-39 (UGT1A6),
59-gttgcgaactgactttgttttggag-39 (UGT1A7), 59-ggtcttcgccaggggaa-
tagg-39 (UGT1A8), 59-ttctccaaacacctgttacggag-39 (UGT1A9), 59-
Table 1. Relative expression levels of UGT1A isoforms among multiple human tissue samples.
..................................................................................................................................................
Placenta Kidney Pancreas Thymus Prostate Testis
Small
intestine Thyroid Bladder Lymphoblast Tonsil Liver Lung
UGT1A1 1 1 1 3 3
UGT1A3 4 10
UGT1A4 4 11
UGT1A5 4 2
UGT1A6 3 7223 16 3 4 3
UGT1A7 2 1 1 1 1 3
UGT1A8 1 1 1 3
UGT1A9 5111 1 1 3 4
UGT1A10 3 1 3 1 3 1 3
doi:10.1371/journal.pone.0000396.t001
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ccaatgaagaccatgttgggc-39) was shared by all UGT1A genes. PCR
reactionsweredenatured initially at95uC for 1 min,and then cycled
35 timesat 95uC for 30s, annealing and extension at 65uCf o r3m i n .
GAPDH gene was amplified with same conditions as above by using
primers 59-tgaaggtcggagtcaacggatttggt-39 and 59-catgtgggccatgaggt-
ccaccac-39 and served as an internal control for cDNA quantity and
quality.
DNA sequences of UGT1A isoforms
The GenBank/NCBI reference sequence for human UDP-
glucuronosyltransferase 1 family, polypeptide A cluster on
chromosome 2 (NG_002601) was used to retrieve the following
regions for the UGT1A isoforms.
a) Promoter regions; The putative promoter regions of the nine
functional UGT1A isoforms are defined as the sequences of
1-3000 bp upstream of the transcription start sites (TSS).
b) Intron 1 sequences; Because the shortest intron 1 (UG-
T1A1’s) is less than 6 kb and the 39 ends of the intron 1
sequences are shared among the isoforms, we scanned the 5
kb segments immediately downstream of the first exons of the
nine functional UGT1A isoforms.
c) Exon 1 sequences: The exon 1 sequences of the nine func-
tional UGT1A isoforms are distinct, so they were included in
the analysis.
Identification of expression-pattern-linked
nucleotides
The nucleotide sequences of the UGT1A isoforms were aligned
using CLUSTAL W [14] (default settings) at the European
Bioinformatics Institute web site (http://www.ebi.ac.uk/clustalw/).
The alignments and the original DNA sequences are provided in the
supplemental materials. The multiple alignments were then scanned
for those nucleotides that were linked to a particular expression
pattern for each isoform and each tissue type. Therefore, the
expression-pattern-linked nucleotides are in the form of an ordered
vector Nt=[n 1(p1),n2(p2),…nj(pj)], where Nt represents the vector of
specific nucleotides for tissue t, n is a particular nucleotide, p is an
integer for the position in an alignment. The elements of Nt are
[nj(pj):y(pj)], where y represents the set of conserved nucleotides of
UGT1Aisoformswithexpressioninaparticulartissue ata particular
position p. The identified nucleotides and their flanking sites (25 bp
upstream/downstream) were then output as entries of the database.
Figure 1. Expression of UGT1A isoforms among multiple human tissue samples. For each functional UGT1A isoform (A through I), an example for the
PCR gels for expression in multiple human tissues together with molecular weight markers is shown.
doi:10.1371/journal.pone.0000396.g001
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Match
To show an example that the database comprised of expression-
pattern-linked nucleotides could be used to generate focused
hypotheses on tissue-specific expression, we used the Match [15]
program at the Gene Regulation web site (http://www.gene-
regulation.com/) to predict the transcription factor binding sites
(TFBS) in the regions that contain one of the liver-specific
nucleotides. The Match program searches the TRANSFAC
database [16] for potential TFBS (core cutoff=0.95, matrix
cutoff=0.90) using high quality database for vertebrates [15]. The
search results (TFBS) that cover the expression-pattern-linked
nucleotide were compared with the expression patterns of the
UGT1A isoforms.
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